Drugs / ES104
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05167448 | Feb 2022 → May 2026 overdue | colorectal cancer | Elpiscience (Suzhou) Biopharma, Ltd. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-04-29 | Elpiscience Biopharma, Ltd. | Results VEGF/DLL4 Bispecific Antibody Meets Primary Endpoint in Phase 2/3 Clinical Trial for Biliary Tract Cancer elpiscience.com ↗
The VEGF/DLL4 bispecific antibody (CTX-009/ES104) has successfully achieved its primary endpoint in a Phase 2/3 clinical trial for biliary tract cancer (BTC), showing potential as a new global standard for second-line BTC treatment. |
| 2022-05-06 | Elpiscience Biopharma, Ltd. | Results Positive Interim ES104 Phase 2 Data Reported in Combination with Paclitaxel in Biliary Tract Cancers elpiscience.com ↗
Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, today announced partner Compass Therapeutics reported positive interim ES104 (also known as CTX-009) Phase 2 data in combination with paclitaxel in patients with biliary tract cancers (BTC) . |
| 2021-10-15 | Elpiscience Biopharma, Ltd. | Regulatory Elpiscience Announces CDE Clearance of IND Application for ES104, Next-frontier Anti-angiogenesis Drug elpiscience.com ↗
Elpiscience Biopharma, a global clinical-stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, today announced that Center of Drug Evaluation (CDE) has cleared Elpiscience’s IND application for ES104 to initiate a Phase I clinical trial in China. |
| 2021-10-08 | Compass Therapeutics | Results CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics compasstherapeutics.com ↗
CTX-009 was well tolerated and demonstrated single agent activity in heavily pre-treated patients with solid tumor who are resistant to anti-VEGF therapies, mostly of colorectal and gastric origins |
| 2021-09-10 | Elpiscience Biopharma, Ltd. | Results ES104 (CTX-009/ABL001) Clinical Data Presented at the 2021 AACR-NCI-EORTC International Conference elpiscience.com ↗
ES104 was well tolerated and demonstrated single agent activity in heavily pre-treated patients with solid tumor who are resistant to anti-VEGF therapies, mostly of colorectal and gastric origins; |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ES104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05167448 ↗ |
| Route | Intravenous | “administered via Intravenous infusion” NCT05167448 ↗ |